QV Investors Inc. Acquires 81,870 Shares of Novo Nordisk A/S $NVO

Key Points

• QV Investors increased its Novo Nordisk stake by 28.5% in the second quarter, purchasing 81,870 additional shares to hold 369,468 shares valued at approximately $17.7 million. Institutional investors collectively own 11.54% of the company.
• Novo Nordisk reported quarterly revenue of $11.98 billion and EPS of $0.94, with a 35.36% net margin and 61.20% return on equity. The stock opened at $46.75, while its average analyst rating remains “Hold” with a $64.94 price target.
• The company’s oral Wegovy offers a potential growth avenue, but intensifying competition from Eli Lilly, pricing pressure, flat Wegovy sales and pipeline setbacks remain key risks. Recent analyst actions have been mixed, including upgrades to “Hold” or “Buy” and a Berenberg downgrade to “Hold.”

QV Investors Inc. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 28.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 369,468 shares of the company's stock after buying an additional 81,870 shares during the period. Novo Nordisk A/S accounts for about 1.4% of QV Investors Inc.'s investment portfolio, making the stock its 25th biggest holding. QV Investors Inc.'s holdings in Novo Nordisk A/S were worth $17,712,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Revolve Wealth Partners LLC raised its position in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC grew its stake in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock valued at $4,312,000 after purchasing an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock worth $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. raised its holdings in Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company's stock worth $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $314,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 0.8%

NYSE:NVO opened at $46.75 on Friday. The company has a market cap of $208.74 billion, a PE ratio of 11.43, a P/E/G ratio of 4.23 and a beta of 0.76. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company's 50 day moving average is $47.30 and its two-hundred day moving average is $44.50.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The business had revenue of $11.98 billion during the quarter. Analysts anticipate that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be given a $0.5786 dividend. This represents a dividend yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S's dividend payout ratio is presently 42.79%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market will not be “winner-take-all,” arguing that patients’ differing preferences and demand for pills, injectables and other differentiated treatments should support multiple successful players. Reuters article
• Positive Sentiment: Novo’s oral Wegovy appears to be generating strong prescription momentum, offering a potential new growth channel and helping the company compete beyond its injectable portfolio. However, investors are watching whether that momentum can offset Lilly’s faster growth. Zacks article
• Positive Sentiment: Zacks Research upgraded NVO from “strong sell” to “hold,” indicating that the stock’s sharp decline and low earnings multiple may have reduced some downside risk.
• Neutral Sentiment: Novo defended its lawsuit challenging Eli Lilly’s weight-loss advertising, saying competition must be fair. The litigation could protect Novo’s marketing position, but it also highlights the intensity of the competitive battle. CNBC article
• Neutral Sentiment: Novo’s CEO continues to promote a long runway for obesity treatments, citing low overall adoption and potential healthcare-cost benefits. These are long-term opportunities rather than immediate earnings catalysts. Fox Business article
• Negative Sentiment: Eli Lilly’s growing share in both injectable and oral weight-loss drugs is the main concern. Analysts warn that Lilly’s momentum could widen the competitive gap and limit the upside investors had anticipated from the Wegovy pill. Yahoo Finance article
• Negative Sentiment: Berenberg downgraded Novo from “buy” to “hold,” citing expectations that the initial Wegovy-pill upside is already reflected in the stock and valuing the company closer to the broader European pharmaceutical sector.
• Negative Sentiment: Recent analysis also points to flat Wegovy sales, pricing pressure and pipeline setbacks as near-term risks, helping explain why NVO has decreased despite its strong margins and broader cardiometabolic pipeline. Zacks analysis

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Friday, June 19th. Weiss Ratings raised shares of Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. Citigroup reiterated a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Finally, Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $64.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source